… PCSK9 inhibitors and placebo. PCSK9 inhibitors are increasingly used in clinical practice
and are incorporated in updates of clinical treatment guidelines based on these trial results […

… PCSK9 inhibitors (PCSK9i), a class of hypolipidemic monoclonal antibodies, is extremely
promising. PCSK9 inhibition … , with potential for very significant clinical repercussions, as every …

… By sequestering PCSK9, the PCSK9 inhibitors block the binding of PCSK9 protein to the
LDLR. … The PCSK9 inhibitors prolong the functional life span of, and amplify the effect of, each …

… In randomized clinical trials, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)
effectively reduce low-density lipoprotein-cholesterol (LDL-C) with a favorable tolerability …

… Ezetimibe plus statins PCSK9 inhibitors plus statins or People adding a second lipid-lowering
drug We suggest adding ezetimibe first Strong All or nearly all informed people would …

… ] on PCSK9 inhibitors in clinical practice, patients were treated with PCSK9 inhibitors for a
relatively short period. Therefore, some possible adverse effects could not be seen. It has to …

… On the other hand, PCSK9 inhibitors in recent experiments and clinical trials within phases
II and III showed little influence on HDL level and on the associated ApoA1. OSLER study …

… document on the indications of PCSK9 inhibitors (PCSK9i) in clinical practice that was
published in 2016. This update is justified by the fact that the data from clinical trials carried out on …

… -lowering therapy, who received PCSK9 inhibitors during the period 2016 to January 2020.
… clinical practice of patients with heterozygous FH with two monoclonal antibodies to PCSK9, …

… of modern clinical medicine, efforts to implement PCSK9 inhibitors (… inhibition of PCSK9
in clinical practice through introduction of a new model of care delivery—the PCSK9i clinic…